CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
panobinostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01496118
NCT01496118Phase 2Completed
CompareCT.gov

Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

SCRI Development Innovations, LLC·interventional·Posted Dec 21, 2011·Updated Feb 2, 2022

In Brief

A Phase 2 clinical trial evaluating panobinostat and carfilzomib for Multiple Myeloma. Completed, enrolled 80 participants across 13 sites.

Detailed Summary

Relapsed/refractory Multiple Myeloma (MM) is an incurable disorder with a poor prognosis. Carfilzomib is a novel proteasome inhibitor with activity in this setting. Panobinostat is a pan-deacetylase inhibitor which has shown synergistic cytotoxicity in vitro and in vivo with proteasome inhibitors. The combination should enhance the activity of both agents against myeloma cells. In Phase I, the optimal doses of the combination of carfilzomib and panobinostat will be determined. Assuming this combination is feasible, the Phase II portion will proceed using the doses determined in Phase I.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsOnyx Therapeutics, Inc., Novartis

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 21, 2011
Enrollment StartDec 1, 2011
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 9 yearsPosted 14.5 years ago

Interventions

panobinostatdrug

Specified dose on specified days

carfilzomibdrug

Specified dose on specified days